Figure 2.

PFS and OS recorded in mNSCLC patients receiving Nivolumab as salvage therapy (a Log-rank test). (A and B) Comparative results between patients who showed or did not show clinical evidence of autoimmunity. (C and D) Comparative results among patients who did not exhibited an increase in serum AAbs (ANA, ENA, and ASMA), patients who exhibited an increase in one of the three AAbs (score 1) and patients who exhibited an increase in two or three AAbs (Score 2). PFS, progression free survival; OS, overall survival; mNSCLC, metastatic non-small cell lung cancer; AAbs, auto antibodies.